HAP Trading’s Neurocrine Biosciences NBIX Stock Holding History

HAP Trading’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-35,884	Closed	-$3.97M	–	849
2025 Q1	$3.97M	Buy	+35,884	New	+$4.55M	0.42%	45

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HAP Trading's NBIX Position: Q2 2025 in Review

HAP Trading sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 35,884 shares — an estimated $3.97M sold.

HAP Trading first reported a position in NBIX in Q1 2025 and held it in 1 quarter. The position peaked at $3.97M in Q1 2025. 586 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

HAP Trading reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
HAP Trading sold 35,884 Neurocrine Biosciences shares in Q2 2025, an estimated $3.97M.
HAP Trading first reported a position in Neurocrine Biosciences in Q1 2025 and held it in 1 quarter.
HAP Trading's Neurocrine Biosciences position peaked at $3.97M in Q1 2025.
586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on HAP Trading's 13F filing for Q2 2025, filed 13 Aug 2025.